Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D.

J Clin Oncol. 2001 Apr 1;19(7):1985-92.

PMID:
11283131
2.

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE.

J Clin Oncol. 2000 Jan;18(2):371-5.

PMID:
10637252
3.

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.

Zhai S, Senderowicz AM, Sausville EA, Figg WD.

Ann Pharmacother. 2002 May;36(5):905-11. Review.

PMID:
11978170
4.

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA.

J Clin Oncol. 1998 Sep;16(9):2986-99.

PMID:
9738567
5.

A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ.

Clin Cancer Res. 2001 Jun;7(6):1590-9.

6.

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.

Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, Wainman N, Colevas AD, Eisenhauer EA.

Invest New Drugs. 2004 Aug;22(3):315-22.

PMID:
15122079
7.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.

Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G.

Cancer Chemother Pharmacol. 2002 Dec;50(6):465-72. Epub 2002 Oct 2.

PMID:
12451473
8.

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.

Kelland LR.

Expert Opin Investig Drugs. 2000 Dec;9(12):2903-11. Review.

PMID:
11093360
9.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM.

J Clin Oncol. 2002 Oct 1;20(19):4074-82.

PMID:
12351605
10.

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

Van Veldhuizen PJ, Faulkner JR, Lara PN Jr, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED; Southwest Oncology Group.

Cancer Chemother Pharmacol. 2005 Jul;56(1):39-45. Epub 2005 Mar 25.

PMID:
15791454
11.

The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6052-61.

12.

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.

Shapiro GI.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s. Review.

13.

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D.

J Clin Oncol. 2002 Apr 15;20(8):2157-70.

PMID:
11956278
14.

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.

Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM.

Clin Cancer Res. 2004 Aug 1;10(15):5038-47.

15.

Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.

Tan AR, Swain SM.

Semin Oncol. 2002 Jun;29(3 Suppl 11):77-85. Review.

PMID:
12138401
16.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.

Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JH 4th, Steiner F, Schrump DS.

J Thorac Cardiovasc Surg. 2003 May;125(5):1132-42.

17.

A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I.

Am J Clin Oncol. 2010 Aug;33(4):393-7. doi: 10.1097/COC.0b013e3181b2043f.

PMID:
19884803
18.

Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.

Wang LM, Ren DM.

Mini Rev Med Chem. 2010 Oct;10(11):1058-70. Review.

PMID:
21047304
19.

Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.

Raju U, Ariga H, Koto M, Lu X, Pickett J, Valdecanas D, Mason KA, Milas L.

Radiother Oncol. 2006 Aug;80(2):185-91. Epub 2006 Aug 14.

PMID:
16905211
20.

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.

Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G; Children's Oncology Group Study.

J Clin Oncol. 2005 Dec 20;23(36):9179-86.

PMID:
16361620

Supplemental Content

Support Center